Celularity Inc
For the period ended Dec 31, 2024. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 8, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · Additional Paid-in · Accumulated · Accumulated Other Comprehensive · Total Stockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balances at January 1, 2023 | 14,892,129 | $15 | $844,373 | $(645,496) | $9 | $198,901 |
| Issuance of common stock in Registered Direct Offering, net of offering expenses | 1,780,220 | 2 | 1,320 | — | — | 1,322 |
| Common stock issued pursuant to short-term debt maturity extension | 270,731 | — | 712 | — | — | 712 |
| Exercise of stock options | 108,637 | — | 304 | — | — | 304 |
| Fair value of warrant modification for professional services | — | — | 403 | — | — | 403 |
| Issuance of common stock for stem-cells to be used in research and development | 169,492 | — | 1,000 | — | — | 1,000 |
| Issuance of warrants to RWI and C.V. Starr | — | — | 2,290 | — | — | 2,290 |
| Common stock issued pursuant to short-term debt conversion | 559,481 | 1 | 4,598 | — | (155) | 4,444 |
| Vesting of restricted stock units | 83,759 | — | — | — | — | 0 |
| Tax withholding on vesting of restricted stock units | (19,130) | — | (101) | — | — | (101) |
| Stock-based compensation expense | — | — | 15,017 | — | — | 15,017 |
| Issuance of common stock in PIPE Offering, net of offering expenses | 1,519,579 | 1 | 12,680 | — | — | 12,681 |
| Issuance of common stock under ATM Agreement | 13,296 | — | 136 | — | — | 136 |
| Change in fair value of debt due to change in credit risk, net of tax | — | — | — | — | 146 | 146 |
| Net loss | — | — | — | (196,295) | — | (196,295) |
| Balances at December 31, 2023 | 19,378,192 | 19 | 882,732 | (841,791) | — | 40,960 |
| Issuance of common stock and warrants in PIPE Offering, net of offering expenses | 2,141,098 | — | 6,000 | — | — | 6,000 |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | 116,964 | — | 317 | — | — | 317 |
| Issuance and modification of warrants to RWI and C.V. Starr | — | — | 3,261 | — | — | 3,261 |
| Exercise of stock options | 20,744 | — | 58 | — | — | 58 |
| Retirement of shares in connection with reverse stock split | (191) | (17) | 17 | — | — | — |
| Issuance of common stock to Palantir as consideration for settlement agreement | 60,584 | — | 175 | — | — | 175 |
| Stock-based compensation expense | — | — | 11,569 | — | — | 11,569 |
| Reclassification of warrants from liability classified to equity classified | — | — | 2,970 | — | — | 2,970 |
| Change in fair value of debt due to change in credit risk, net of tax | — | — | — | — | (5) | (5) |
| Vesting of restricted stock units | 401,013 | — | — | — | — | — |
| Tax withholding on vesting of restricted stock units | (109,790) | — | (434) | — | — | (434) |
| Common stock issued pursuant to short-term debt conversion | 478,881 | — | 1,700 | — | — | 1,700 |
| Issuance of common stock as compensation expense | 59,176 | — | 158 | — | — | 158 |
| Net loss | — | — | — | (57,892) | — | (57,892) |
| Balances at December 31, 2024 | 22,546,671 | $2 | $908,523 | $(899,683) | $(5) | $8,837 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.